Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Halperin

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
BMC Medical Informatics and Decision Making|June 26, 2019
The Generalized Data Model for clinical researchMark D Danese, Marc Halperin, Jennifer Duryea, et al.
Medical Care|January 14, 2016
Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World DataMark D Danese, Carolina M Reyes, Michelle L Gleeson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 31, 2015
Refining the definition of clinically important mineral and bone disorder in hemodialysis patientsMark D Danese, Marc Halperin, Kimberly A Lowe, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|October 5, 2020
Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trialGeoffrey A Block, Glenn M Chertow, Kerry Cooper, et al.
Journal of Medical Economics|March 14, 2012
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United StatesAlison Stopeck, Michael Rader, David Henry, et al.
JAMA Network Open|November 16, 2019
Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell DiseaseDeborah Lubeck, Irene Agodoa, Nickhill Bhakta, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|January 20, 2016
Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998-2011Deborah P Lubeck, Mark D Danese, Jennifer Duryea, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
BMC Medical Informatics and Decision Making|June 26, 2019
The Generalized Data Model for clinical researchMark D Danese, Marc Halperin, Jennifer Duryea, et al.
Medical Care|January 14, 2016
Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World DataMark D Danese, Carolina M Reyes, Michelle L Gleeson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 31, 2015
Refining the definition of clinically important mineral and bone disorder in hemodialysis patientsMark D Danese, Marc Halperin, Kimberly A Lowe, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|October 5, 2020
Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trialGeoffrey A Block, Glenn M Chertow, Kerry Cooper, et al.
Journal of Medical Economics|March 14, 2012
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United StatesAlison Stopeck, Michael Rader, David Henry, et al.
JAMA Network Open|November 16, 2019
Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell DiseaseDeborah Lubeck, Irene Agodoa, Nickhill Bhakta, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|January 20, 2016
Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998-2011Deborah P Lubeck, Mark D Danese, Jennifer Duryea, et al.
Pageof 1